S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
Log in

Axcella Health Stock Price, Forecast & Analysis (NASDAQ:AXLA)

$3.83
-0.12 (-3.04 %)
(As of 11/13/2019 04:00 PM ET)
Today's Range
$3.60
Now: $3.83
$4.00
50-Day Range
$4.22
MA: $5.31
$6.93
52-Week Range
$3.47
Now: $3.83
$15.99
Volume24,300 shs
Average Volume30,492 shs
Market Capitalization$88.40 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for Axcella Health Inc.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXLA
CUSIPN/A
CIKN/A
Phone857-320-2200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$88.40 million
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable

Receive AXLA News and Ratings via Email

Sign-up to receive the latest news and ratings for AXLA and its competitors with MarketBeat's FREE daily newsletter.


Axcella Health (NASDAQ:AXLA) Frequently Asked Questions

What is Axcella Health's stock symbol?

Axcella Health trades on the NASDAQ under the ticker symbol "AXLA."

How were Axcella Health's earnings last quarter?

Axcella Health Inc (NASDAQ:AXLA) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.75) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.71) by $0.04. View Axcella Health's Earnings History.

When is Axcella Health's next earnings date?

Axcella Health is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Axcella Health.

What price target have analysts set for AXLA?

4 analysts have issued 1-year price objectives for Axcella Health's stock. Their forecasts range from $20.00 to $25.00. On average, they anticipate Axcella Health's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 474.4% from the stock's current price. View Analyst Price Targets for Axcella Health.

What is the consensus analysts' recommendation for Axcella Health?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axcella Health.

Has Axcella Health been receiving favorable news coverage?

News stories about AXLA stock have been trending very negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Axcella Health earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Axcella Health.

Are investors shorting Axcella Health?

Axcella Health saw a drop in short interest in September. As of September 30th, there was short interest totalling 40,000 shares, a drop of 7.6% from the August 30th total of 43,300 shares. Based on an average daily volume of 12,300 shares, the days-to-cover ratio is currently 3.3 days. Currently, 0.5% of the shares of the stock are sold short. View Axcella Health's Current Options Chain.

Who are some of Axcella Health's key competitors?

What other stocks do shareholders of Axcella Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Triton International (TRTN), Main Street Capital (MAIN), Achillion Pharmaceuticals (ACHN), Adobe (ADBE), Blackline (BL), Coda Octopus Group (CODA), Exelixis (EXEL), Stamps.com (STMP), Xilinx (XLNX) and Delek US (DK).

When did Axcella Health IPO?

(AXLA) raised $76 million in an IPO on Thursday, May 9th 2019. The company issued 3,600,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink acted as the underwriters for the IPO.

When did the company's lock-up period expire?

Axcella Health's lock-up period expired on Tuesday, November 5th. Axcella Health had issued 3,571,428 shares in its initial public offering on May 9th. The total size of the offering was $71,428,560 based on an initial share price of $20.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.

How do I buy shares of Axcella Health?

Shares of AXLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Axcella Health's stock price today?

One share of AXLA stock can currently be purchased for approximately $3.83.

How big of a company is Axcella Health?

Axcella Health has a market capitalization of $88.40 million. View Additional Information About Axcella Health.

What is Axcella Health's official website?

The official website for Axcella Health is http://www.axcellahealth.com/.

How can I contact Axcella Health?

Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-320-2200.


MarketBeat Community Rating for Axcella Health (NASDAQ AXLA)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  27 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  60
MarketBeat's community ratings are surveys of what our community members think about Axcella Health and other stocks. Vote "Outperform" if you believe AXLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXLA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel